Opinion|Videos|March 4, 2025
Long-Term Use of Topical Treatments in Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD, Randy Alevi, DO
Panelists discuss how the newer topical agents (PDE4 inhibitors, JAK inhibitors) demonstrate comparable efficacy to midpotency corticosteroids but with improved safety profiles, lacking steroid-related adverse effects such as skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and tachyphylaxis when used long term.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do the long-term efficacy and safety profiles of these newer agents compare with topical corticosteroids?
Advertisement
Related to this article
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
3
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
4
More Frequent Physical Activity Linked to Fewer Perimenopause Symptoms in Global Study
5